Scripps Cancer Center's 39th Annual Conference: Clinical Hematology & Oncology 2019
Targeting FLT3 mutations in AML: Daunorubicin, Midostaurin, Sorafenib, Quizartinib, Gilteritinib
Login to view comments.
Click here to Login
Malignant Hematology